Abstract |
In evaluating any randomized clinical trial, it is important to determine whether baseline differences between groups could have affected the primary outcome. In our study, muscle insulin sensitivity, which was identical in both groups at baseline, improved after nicotinamide mononucleotide (NMN), not placebo, therapy. Differences in baseline intrahepatic triglyceride content between groups do not negate the effects of NMN observed in muscle.
|
Authors | Samuel Klein, Mihoko Yoshino |
Journal | Science (New York, N.Y.)
(Science)
Vol. 373
Issue 6554
(07 30 2021)
ISSN: 1095-9203 [Electronic] United States |
PMID | 34326209
(Publication Type: Journal Article, Comment)
|
Copyright | Copyright © 2021, American Association for the Advancement of Science. |
Chemical References |
- Triglycerides
- Nicotinamide Mononucleotide
|
Topics |
- Female
- Humans
- Insulin Resistance
- Muscles
- Nicotinamide Mononucleotide
- Prediabetic State
(drug therapy)
- Triglycerides
|